Brief: Inflarx Completes Enrollment In Phase IIb Clinical Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa
08/11/2018 08:28
Nov 8 (Reuters) - Inflarx NV IFRX.O :
* INFLARX COMPLETES ENROLLMENT IN PHASE IIB CLINICAL TRIAL
WITH
LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA
* INFLARX NV SAYS TRIAL RESULTS ANTICIPATED FIRST HALF 2019
Source text for Eikon: ID:nGNX4xQs2B
Further company coverage: IFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum